Navigation Links
Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients
Date:10/22/2008

- MDV3100 Continues to Show Encouraging and Durable Anti-Tumor Activity and

Dose Escalation Continues - - Results Presented at the 20th EORTC-NCI-AACR Symposium on Molecular

Targets and Cancer Therapeutics -

GENEVA and SAN FRANCISCO, Oct. 22 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced the presentation of new data from an ongoing Phase 1-2 clinical trial demonstrating that the Company's novel androgen receptor antagonist MDV3100 continues to show promising safety and efficacy results. The data showed encouraging and durable anti-tumor activity in the three expanded dose groups tested thus far, as measured by prostate specific antigen (PSA) declines, radiographic findings, circulating tumor cell (CTC) changes, and time on treatment. MDV3100 has been generally well tolerated, with no reports of serious adverse events deemed related to MDV3100. Dose escalation in the trial is continuing.

"The tolerability and the anti-tumor activity seen with MDV3100 after six months of treatment remains encouraging," said Howard Scher, M.D., principal investigator of the trial and chief of the Genitourinary Oncology Service and the D. Wayne Calloway Chair in Urologic Oncology at Memorial Sloan-Kettering Cancer Center. "The trial continues to enroll rapidly and additional data will further clarify the potential of MDV3100 as a treatment option for patients with castration-resistant prostate cancer, who have a poor prognosis and for whom treatment options are limited."

MDV3100 Trial Design and Results to Date

The ongoing Phase 1-2 trial is an open-label U.S. dose-escalation study in prostate cancer patients who have failed standard hormonal therapies. To d
'/>"/>

SOURCE Medivation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Medivation Receives Corporate Achievement Award From Huntingtons Disease Society of America
2. Medivation to Host Conference Call at 8:30 a.m. Eastern Time Tomorrow to Discuss Partnering Plans for Dimebon
3. Medivation Announces Participation in Upcoming Conferences
4. Medivation Reports Second Quarter 2008 Financial Results and Provides Corporate Update
5. Medivation Announces Second Quarter 2008 Teleconference and Webcast on August 11, 2008
6. Medivation Announces Presentation at the BMO Capital Markets 2008 Focus on Healthcare Conference on August 5
7. Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients
8. Medivation Announces Senior Management Promotions
9. Medivation Reports Year-End 2007 Financial Results and Pipeline Progress
10. Medivation Announces Participation in Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
11. Medivation Selected as Founding Member of New NASDAQ(R) NeuroInsights(R) Neurotech Index
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... BARCELONA, Spain , April 27, 2015  Together ... during the 3rd ESTRO Forum in Barcelona ... Hope, a nonprofit organization with the mission to improve ... Radiating Hope believes that no patient should ... is not affordable. Consequently, it cooperates with hospitals and ...
(Date:4/24/2015)... 24, 2015 Leading Regenerative Veterinary ... its allogeneic stem-cell product development program and changes ... the corporate strategic direction. , “I am extremely ... stem cell development program has been kicked into ... manufacturing facility and hiring of our new Director ...
(Date:4/24/2015)... , April 24, 2015  Navitas Life Sciences is delighted ... Head of Clinical and Regulatory Services. Shalabh is a proven ... co-founder and CEO of Kinapse, as well as a Strategy ... Logo - http://photos.prnewswire.com/prnh/20150423/201261LOGO ... commented "I am delighted to welcome Shalabh into this ...
(Date:4/23/2015)... Dora, Florida (PRWEB) April 23, 2015 ... that it intends to conduct a groundbreaking pilot ... begin to be reversed in as little as ... the science of metabolic and nutritional medicine—will aggressively ... that cripple and destroy our aging brain. These ...
Breaking Biology Technology:Elekta helps raise $33,000 to bring radiation treatment to developing countries 2Elekta helps raise $33,000 to bring radiation treatment to developing countries 3Vet-Stem, Inc. Meets New Milestones and Changes Name to VetStem Biopharma 2Shalabh Kumar Joins Navitas Life Sciences to Lead their Clinical and Regulatory Services Teams 2New Study Looks to Reverse Alzheimer’s Disease 2New Study Looks to Reverse Alzheimer’s Disease 3
... Cephalon, Inc., (Nasdaq: CEPH ) will hold a public ... late Chairman and CEO on February 1, 2011, at 6:00 p.m. ... Pennsylvania. Dr. Baldino founded Cephalon in 1987 and ... the top ten biotechnology companies in the world. He was a ...
... SHANGHAI, Jan. 24, 2011 /PRNewswire-Asia-FirstCall/ -- China-Biotics, Inc. ("China-Biotics" ... leading developer, manufacturer and distributor of probiotics products in ... 2011 third quarter ended December 31, 2010. ... between $32 million and $33 million compared with $23 ...
... Jan. 24, 2011 RRD International, a strategy-driven biotech ... has entered into a partnership with the National Institutes ... (TRND) program as a regulatory support and development partner. ... focus on two rare disease drug development projects: Hereditary ...
Cached Biology Technology:Cephalon to Hold Public Memorial Service to Celebrate the Life of Company Founder, Frank Baldino, Jr., Ph.D. 2China-Biotics, Inc. Provides Preliminary FY2011Third Quarter Revenue 2China-Biotics, Inc. Provides Preliminary FY2011Third Quarter Revenue 3RRD Selected as Development Partner for NIH Therapeutics for Rare and Neglected Diseases Program 2RRD Selected as Development Partner for NIH Therapeutics for Rare and Neglected Diseases Program 3
(Date:4/13/2015)... -- higi, a leading cloud-based consumer engagement platform that provides ... their communities around health and wellness, announced today the ... ... convenient vehicle to receive validated health information from consumers. ... API will allow higi,s trusted partners, on a user ...
(Date:4/2/2015)... 2015 In the current ... outperforms the strongest competitors, showing outstanding performance in ... system is capable of a throughput of 5.000.000 ... to be ten times faster than most competitors ...      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ) ...
(Date:4/1/2015)... April 1, 2015   Medisafe ™, the leading ... across iOS and Android smartphones ... biofeedback into the platform to allow patients to track ... the first time, patients will be able to visualize ... impacts important biometrics, such as glucose levels and blood ...
Breaking Biology News(10 mins):higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2
... release is available in German . , In ... immune system must be able to recognize myriad different foreign ... Institute of Immunobiology and the Centre for Biological Signalling Studies ... immune system,s B-cells can be activated by numerous substances from ...
... know about smoking, diet, exercise and available methods ... approximately half of all cancers nationwide. ... will host its Ninth Annual International Conference on ... Convention Center, located in Philadelphia. Thousands of scientists ...
... new study from North Carolina State University finds that fish ... than fish that live much further away. The surprising finding ... selenium, found near such facilities, which unfortunately poses problems of ... at least 30 kilometers (km) from a coal-fired power plant ...
Cached Biology News:One lock, many keys 2Study: Fish near coal-fired power plants have lower levels of mercury 2
Mouse monoclonal [3F8 ] to smooth muscle Myosin heavy chain I ( Abpromise for all tested applications). entrezGeneID: 4629 SwissProtID: P35749...
Request Info...
Goat polyclonal to SART1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: GSSKKHRGEKEAA, corresponding to N terminal amino acids 2-14 of Human SART1. Entrez Gene ID: 909...
...
Biology Products: